KPC Pharmaceuticals' (SHA:600422) attributable profit rose 20% to 648.1 million yuan in 2024 from 540.7 million yuan in 2023.
Earnings per share at the drug company increased 21% to 0.86 yuan from 0.71 yuan in the previous year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320) with the Hong Kong bourse.
Revenue slipped 0.3% to 8.40 billion yuan from 8.43 billion yuan a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。